Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan.
Department of Urology, Fujita Health University Okazaki Medical Center, Okazaki, Japan.
BJU Int. 2024 Sep;134(3):426-433. doi: 10.1111/bju.16340. Epub 2024 Mar 19.
To determine whether an enhanced recovery after surgery (ERAS) protocol enhances bowel recovery and reduces postoperative ileus (POI) in both non-frail and frail patients after robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC).
This retrospective cohort study included 186 patients (104 with and 82 without ERAS) who underwent iRARC between 2012 and 2023. 'Frail' patients was defined as those with a low Geriatric-8 questionnaire score (≤13). The primary outcomes were postoperative bowel recovery and the incidence of POI. Secondary outcomes included length of stay (LOS), 30- and 90-day complications, 90-day readmission rate, and POI predictors.
The ERAS group exhibited a significantly shorter LOS, early bowel recovery, a lower POI rate, fewer 90-day high-grade complications, and fewer 90-day readmissions than the non-ERAS group in the entire cohort. Non-frail patients in the ERAS group had a lower rate of POI (7.1% vs. 22.1%; P = 0.008), whereas ERAS did not reduce POI in frail patients (44.1% vs. 36.6%; P = 0.50). In the multivariate analysis, ERAS was associated with a reduced risk of POI in both the entire cohort (odds ratio [OR] 0.39, P = 0.01) and in non-frail patients (OR 0.24, P = 0.01), whereas ERAS was not likely to reduce POI (OR 1.14, P = 0.70) in frail patients. Prehabilitation was identified as a favourable predictor of POI.
The ERAS protocol did not reduce POI in frail patients after iRARC, although it enhanced bowel recovery and reduced POI in non-frail patients. Prehabilitation for frail patients might reduce POI.
确定在机器人辅助根治性膀胱切除术(iRARC)联合腔内尿流改道术中,强化术后康复(ERAS)方案是否能促进非虚弱和虚弱患者的肠道恢复并减少术后肠梗阻(POI)。
本回顾性队列研究纳入了 186 例患者(104 例接受 ERAS,82 例未接受 ERAS),他们于 2012 年至 2023 年间接受了 iRARC。“虚弱”患者被定义为老年 8 项问卷评分(≤13 分)较低的患者。主要结局是术后肠道恢复和 POI 的发生率。次要结局包括住院时间(LOS)、30 天和 90 天并发症、90 天再入院率和 POI 的预测因素。
在整个队列中,ERAS 组的 LOS 明显缩短,肠道早期恢复,POI 发生率较低,90 天高级别并发症较少,90 天再入院率较低。ERAS 组非虚弱患者的 POI 发生率较低(7.1% vs. 22.1%;P=0.008),而 ERAS 并不能降低虚弱患者的 POI(44.1% vs. 36.6%;P=0.50)。多变量分析显示,ERAS 与整个队列(优势比 [OR] 0.39,P=0.01)和非虚弱患者(OR 0.24,P=0.01)POI 风险降低相关,而 ERAS 不太可能降低虚弱患者的 POI(OR 1.14,P=0.70)。术前康复被确定为 POI 的有利预测因素。
在 iRARC 后,ERAS 方案并未降低虚弱患者的 POI,尽管它促进了非虚弱患者的肠道恢复并降低了 POI。虚弱患者的术前康复可能会降低 POI。